Vasomune is a private biopharmaceutical company developing the next generation of medications to harness the body’s ability to defend against illness.
Toronto, Canada
Joined November 2019
- Tweets58
- Following587
- Followers105
- Likes28
Health Canada approves a new trial for Pegevongitide (AV-001) — a made-in-Canada therapy co-developed by Vasomune & AnGes — to protect hemodialysis patients from brain injury by stabilizing the cerebrovasculature.
Vasomune Therapeutics, Inc. retweeted
🧬Next up as part of our #GlobalBiotechWeek celebration is @vasomune who reached the milestone of receiving U.S. FDA Fast Track Designation for their novel investigational medicine AV-001. 👏🏽 We're proud of Vasomune, an #OBIO member, as they continue to advance to the next phase!
Vasomune Therapeutics, Inc. is proud to be in Florida presenting our work at the 2024 Military Health System Research Symposium! With their support we have come a long way from preclinical to Phase 2a with AV-001 for the prevention and treatment of ARDS.
linkedin.com/posts/haroldkim…
Thank you @ARDSALliance and @PaulaBlonski for striving against ARDS, and for reminding us why continued research into prevention and treatment is so important.
linkedin.com/posts/paulablon…
MHSRS-24-11804 (Full title in article) at 2024 Military Health System Research Symposium. Read more in the link below.
linkedin.com/feed/update/urn…
Vasomune Therapeutics, Inc. retweeted
👏🏽Congratulations to @vasomune on this milestone! We are proud of #OBIO member, Vasomune, as they receive U.S. FDA Fast Track Designation for AV-001. Looking forward to seeing you advance to the next phase!
Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001 businesswire.com/news/home/2…
Vasomune Therapeutics, Inc. retweeted
Ft. @brogoz (CEO of @oncoustics), Alison Smith (co-founder and chief scientist at Roga), @FelixBL92 (CEO of @altislabs), Adam Forman (co-founder of Synakis) and Brian Jahns (COO of @vasomune).
Vasomune Therapeutics, Inc. retweeted
These five startups are working on solutions that could speed up diagnosis, develop promising new therapeutics and improve patient care. Check them out at #MaRSImpactHealth happening June 12 and 13.
marsdd.com/news/meet-5-entre…
Vasomune Therapeutics, Inc. retweeted
This week @AstraZeneca completed the acquisition of Genesys portfolio company @FusionPharmaInc for US$2.4B! What a journey it has and we're thrilled to see Ontario becoming a global hub of excellence for radiopharmaceuticals.
prnewswire.com/news-releases…
On Monday, June 5th at 3pm PST, Dr Brian Jahns presents the Vasomune Therapeutics story. Join Brian in Theatre 3 for the story of how Vasomune achieved the Fast Track Designation for pneumonia ARDS, and what his vision for the future is.
convention.bio.org/sessions/…
Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001 businesswire.com/news/home/2…
Vasomune Therapeutics, Inc. retweeted
アンジェス---Vasomuneとの共同開発品「AV-001」が米国呼吸器学会でポスター発表 - 最新株式ニュース dlvr.it/T6ZnpF
On May 21, 2024, Vasomune's Dr. Harold Kim will present Phase 1 safety, and pharmacokinetic and pharmacodynamic data for AV-001 as a late-breaking scientific poster at the American Thoracic Society Clinical and Scientific sessions.
lnkd.in/gYM4HPAk
Vasomune Therapeutics' Dr Harold Kim, has been selected by the American Thoracic Society to showcase our lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit. Dr. Harold Kim, will speak on May 18th, at 11:30 AM PT, at the Manchester Grand Hyatt, San Diego, CA.
The agenda may be found at: lnkd.in/dRujG49e
We are pleased to announce that the Independent Data and Safety Monitoring Board recommended the continuation of the Phase 2a trial (NCT05123755) evaluating the efficacy, safety, and tolerability of AV-001 in patients suffering with Acute Respiratory... businesswire.com/news/home/2…
Vasomune Therapeutics doses first patient in Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease.
businesswire.com/news/home/2…
Our strategic approach to SARS-CoV-2 involves the development of AV-001 for treating patients with severe COVID-19 disease and vaccines to prevent infection businesswire.com/news/home/2…
